disease directly correlates with the level of PD-1 expression. Phagocytosis also appears to decrease due to PD-1 expression in TAMs; thus, PD-L1 removal may lead to PD-1 + TAM phagocytosis and a subsequent reduction in tumor burden, along with a functional recovery of TAMs. It is worth mentioning that PD-1 expression inhibits a wide variety of immune cell subsets, including T cells, B cells, natural killer cells, dendritic cells, and macrophages, in the tumor microenvironment, proposing that PD-1 expression is a global mechanism to restrict immunity, provided via the innate and adaptive immune system. Clinicians have exploited this mechanism for the benefit of breast cancer treatment.
Currently, the use of anti-PD-1/PD-L1 in treatment of breast cancer has received much attention, particularly for the TNBC subtype. TNBC tumors with a highly invasive characteristic express a large amount of PD-L1 and a high degree of tumor-infiltrating lymphocytes compared with other subtypes of breast cancer, implicating the immunogenic nature of TNBC.
Current clinical trials testing for immunotherapy
Currently, an 18% overall response rate is achieved in the phase Ib clinical trial with the PD-1 antibody, pembrolizumab, for intensely-treated TNBC. In this trial, PD-L1 positivity was assigned to the cancer cells expressing PD-L1 by more than 1%, and anti PD-1 antibody response was correlated with the increasing expression of PDL-1. Moreover, a 33% general response was obtained for an anti-PD-L1 antibody, atezolizumab in a phase I trial for metastatic TNBC. An additional study performed on atezolizumab proposed that tumor response is associated with high levels of PDL-1 expression, not in tumor cells, but in tumor-infiltrating immune cells. Furthermore, the anti-PD-1 nivolumab (BMS-936558/MDX-1106) and the anti-PD-L1 durvalumab (MEDI4736) are presently under investigation in breast cancer.
